Loading...
•
Mar 31, 2020
Cogent Biosciences Q1 2020 Earnings Report
Announced financial results for the first quarter ended March 31, 2020, and provided corporate updates.
Key Takeaways
Unum Therapeutics reported a collaboration revenue of $7.0 million for the first quarter of 2020, compared to $3.1 million in the same period of 2019. The net loss attributable to common stockholders was $6.1 million, or $0.20 per share, compared to a net loss of $11.7 million, or $0.39 per share, for the same period in 2019. Cash and cash equivalents totaled $29.6 million as of March 31, 2020.
Prioritizing resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers.
Entered into a common stock purchase agreement for up to $25 million with Lincoln Park Capital Fund, LLC.
Exploring strategic options to maximize shareholder value.
Collaboration revenue increased due to the conclusion of the ATTCK-17-01 Phase 1 clinical trial and the termination of the collaboration agreement.
Forward Guidance
Unum believes that its existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into mid-2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...